Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2262250
Max Phase: Preclinical
Molecular Formula: C25H27ClN2O4S
Molecular Weight: 487.02
Molecule Type: Small molecule
Associated Items:
ID: ALA2262250
Max Phase: Preclinical
Molecular Formula: C25H27ClN2O4S
Molecular Weight: 487.02
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCCC2)C1c1csc(-c2ccc(Cl)cc2)n1
Standard InChI: InChI=1S/C25H27ClN2O4S/c1-14-20(24(29)31-3)22(19-13-33-23(28-19)16-9-11-17(26)12-10-16)21(15(2)27-14)25(30)32-18-7-5-4-6-8-18/h9-13,18,22,27H,4-8H2,1-3H3
Standard InChI Key: FXSSBKJHEAWCGM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 487.02 | Molecular Weight (Monoisotopic): 486.1380 | AlogP: 5.75 | #Rotatable Bonds: 5 |
Polar Surface Area: 77.52 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 1.96 | CX LogP: 5.09 | CX LogD: 5.09 |
Aromatic Rings: 2 | Heavy Atoms: 33 | QED Weighted: 0.54 | Np Likeness Score: -0.85 |
1. Samzadeh-Kermani A, Shafaroodi H, Miri R, Mirkhani H, Vosooghi M, Shafiee A. (2009) Lipophilic 2-(4-chlorophenyl)-4-thiazolyl-1,4-dihydropyridines: synthesis, calcium channel antagonist activity, and protection against pentylenetetrazole-induced seizure, 18 (2): [10.1007/s00044-008-9112-5] |
Source(1):